David McDermott, M.D. discusses new advances made to treat kidney cancer.
The FDA granted Zykadia a priority review for the frontline treatment of some patients with lung cancer.
Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way to more personalized prostate cancer care.
More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings.
A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma.
Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.
The Food and Drug Administration (FDA) approved Revlimid (lenalidomide) for maintenance therapy for some patients with multiple myeloma.
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.
A regimen without gemcitabine had promising survival rates for patients with metastatic pancreatic cancer, according to a recent study.